Second-generation antidepressants for preventing seasonal affective disorder in adults
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This review - one of four reviews on efficacy and safety of interventions to prevent SAD - focuses on second-generation antidepressants (SGAs). OBJECTIVES: To assess the efficacy and safety of SGAs (in comparison with other SGAs, placebo, light therapy, melatonin or agomelatine, psychological therapies or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD. SEARCH METHODS: We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 19 June 2018. An earlier search of these databases was conducted via the Cochrane Common Mental Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 August 2015). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature, Web of Science, the Cochrane Library, the Allied and Complementary Medicine Database and international trial registers (to 19 June 2018). We also conducted a grey literature search and handsearched the reference lists of included studies and pertinent review articles. SELECTION CRITERIA: For efficacy, we included randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. For adverse events, we planned to include non-randomised studies. Eligible studies compared a SGA versus another SGA, placebo, light therapy, psychological therapy, melatonin, agomelatine or lifestyle changes. We also intended to compare SGAs in combination with any of the comparator interventions versus placebo or the same comparator intervention as monotherapy. DATA COLLECTION AND ANALYSIS: statistic to estimate the magnitude of heterogeneity. We assessed publication bias by using funnel plots.We rated the strength of the evidence using the system developed by the GRADE Working Group. MAIN RESULTS: We identified 3745 citations after de-duplication of search results and excluded 3619 records during title and abstract reviews. We assessed 126 full-text papers for inclusion in the review, of which four publications (on three RCTs) providing data from 1100 people met eligibility criteria for this review. All three RCTs had methodological limitations due to high attrition rates.Overall, moderate-quality evidence indicates that bupropion XL is an efficacious intervention for prevention of recurrence of depressive episodes in people with a history of SAD (risk ratio (RR) 0.56, 95% confidence interval (CI) 0.44 to 0.72; 3 RCTs, 1100 participants). However, bupropion XL leads to greater risk of headaches (moderate-quality evidence), insomnia and nausea (both low-quality evidence) when compared with placebo. Numbers needed to treat for additional beneficial outcomes (NNTBs) vary by baseline risks. For a population with a yearly recurrence rate of 30%, the NNTB is 8 (95% CI 6 to 12). For populations with yearly recurrence rates of 50% and 60%, NNTBs are 5 (95% CI 4 to 7) and 4 (95% CI 3 to 6), respectively.We could find no studies on other SGAs and no studies comparing SGAs with other interventions of interest, such as light therapy, psychological therapies, melatonin or agomelatine. AUTHORS' CONCLUSIONS: Available evidence indicates that bupropion XL is an effective intervention for prevention of recurrence of SAD. Nevertheless, even in a high-risk population, three out of four people will not benefit from preventive treatment with bupropion XL and will be at risk for harm. Clinicians need to discuss with patients advantages and disadvantages of preventive SGA treatment, and might want to consider offering other potentially efficacious interventions, which might confer a lower risk of adverse events. Given the lack of comparative evidence, the decision for or against initiating preventive treatment of SAD and the treatment selected should be strongly based on patient preferences.Future researchers need to assess the effectiveness and risk of harms of SGAs other than bupropion for prevention of SAD. Investigators also need to compare benefits and harms of pharmacological and non-pharmacological interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Golden, R. N., Gaynes, B. N., Ekstrom, R. D., Hamer, R. M., Jacobsen, F. M., Suppes, T., Wisner, K. L., & Nemeroff, C. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.656 · Cited by 896
Self-citationLam, R. W., Levitt, A. J., Levitan, R. D., Enns, M. W., Morehouse, R., Michalak, E. E., & Tam, E. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.805 · Cited by 232
Interactions of the serotonin and circadian systems: nature and nurture in rhythms and blues
Ciarleglio, C. M., Resuehr, H. E. S., & McMahon, D. G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.036 · Cited by 151
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
Self-citationThe chronobiology and neurobiology of winter seasonal affective disorder
Levitan, R. D. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.3/rlevitan · Cited by 149
Melatonin and agomelatine for preventing seasonal affective disorder
Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Sonis, J. H., Greenblatt, A., Wipplinger, J., Lux, L. J., Winkler, D., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011271.pub2 · Cited by 39
Self-citationMelatonin and agomelatine for preventing seasonal affective disorder
Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C. A., Morgan, L. C., Gaynes, B. N., Sonis, J. H., Greenblatt, A., Wipplinger, J., Lux, L. J., Hofmann, J., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011271 · Cited by 11
Self-citation
Cited by
Nussbaumer-Streit, B., Klerings, I., Dobrescu, A. I., Persad, E., Stevens, A., Garritty, C., Kamel, C., Affengruber, L., King, V. J., & Gartlehner, G. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.10.011 · Cited by 440
Self-citationMaj, M., Stein, D. J., Parker, G., Zimmerman, M., Fava, G. A., De Hert, M., Demyttenaere, K., McIntyre, R. S., Widiger, T., & Wittchen, H. (2020) · World Psychiatry · doi:10.1002/wps.20771 · Cited by 435
Nussbaumer-Streit, B., Klerings, I., Wagner, G., Heise, T. L., Dobrescu, A. I., Armijo-Olivo, S., Stratil, J. M., Persad, E., Lhachimi, S. K., Van Noord, M. G., et al. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.05.022 · Cited by 72
Self-citationShinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027574 · Cited by 27
Metadata
- Authors
- Gartlehner, G., Nussbaumer, B., Gaynes, B. N., Forneris, C. A., Morgan, L. C., Kaminski-Hartenthaler, A., Greenblatt, A., Wipplinger, J., Lux, L. J., Sonis, J. H., Hofmann, J., Van Noord, M. G., & Winkler, D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-11-08
- Volume
- 3
- Issue
- 11
- Pages
- CD011268-CD011268
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2123058458
- Cited by
- 30
- References
- 7
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second-generation antidepressants for preventing seasonal affective disorder in adults. https://app.cochat.ai/papers/10.1002/14651858.cd011268.pub2
- The paper
- Gartlehner, G., Nussbaumer, B., Gaynes, B. N., Forneris, C. A., Morgan, L. C., Kaminski-Hartenthaler, A., Greenblatt, A., Wipplinger, J., Lux, L. J., Sonis, J. H., Hofmann, J., Van Noord, M. G., & Winkler, D. (2015). Second-generation antidepressants for preventing seasonal affective disorder in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011268.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.